Ichor is dedicated to the clinical application and commercialization of electroporation technology for the delivery of DNA drugs and vaccines to treat and prevent debilitating or life threatening diseases.

Ichor has developed a powerful, patented electroporation technology for DNA drug delivery that will generate significant value for patients, investors and partners. We are applying our proprietary TriGrid™ Delivery System (TDS) to enable delivery of DNA drugs to address unmet medical needs in areas including therapeutic cancer vaccines, therapeutic proteins and vaccines for serious infectious disease. To date, the lack of an effective clinical delivery technology has blocked the development efforts of several promising DNA drugs. The TDS device holds the key to unlocking the potential of many broad families of DNA drugs and DNA vaccines.

To minimize product development risk, Ichor will leverage the investment by others in current DNA drugs with proven safety and characterized efficacy. In such cases, Ichor will integrate the TriGrid™ Delivery System with the DNA drug to enhance delivery and safely drive higher efficacy than can be achieved solely via simple injection of DNA.

Using this strategy, Ichor intends to create a broad portfolio of integrated proprietary products targeting the full range of DNA therapeutic applications. Ichor and its collaboration partners have several development programs currently underway, including multiple sclerosis, HIV, breast cancer, prostate cancer, melanoma, anthrax and HBV.

Revenues of the high-margin integrated products will derive from both the sales of the DNA drug constructs and the sales from the disposable cartridge portion of our TDS device. Both are manufactured using currently available technology at attractive cost of goods.